Item 5.02. Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On January 14, 2022, the Board of Directors of Immuneering Corporation (the "Company") appointed Diana F. Hausman, MD to serve as a member of the Board of Directors as a Class I Director. Dr. Hausman will receive compensation in accordance with the Company's compensation arrangements for non-management directors. Dr. Hausman has not been appointed to a committee of the Board of Directors at this time. There was no arrangement or understanding pursuant to which Dr. Hausman was elected as a director. Dr. Hausman has also entered into the Company's standard indemnification agreement for directors and officers.

On January 18, 2022, the Company issued a press release announcing Dr. Hausman's appointment to the Board of Directors (the "Press Release"). The Press Release is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.






(d) Exhibits



Exhibit No   Description

   99.1        Press Release issued by Immuneering Corporation on January 18, 2022

   104       Cover Page Interactive Data File (embedded within the Inline XBRL document).

© Edgar Online, source Glimpses